Search Within

Melanoma and Immunotherapeutics Service

Formats
  1. Journal Article (957)
  2. Meeting Abstract (774)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1866)
  2. Solid Tumor Oncology Division (1866)
  3. GSK Faculty (1051)
  4. Melanoma Disease Management Team (787)
  5. Hematologic Malignancies, Division of (510)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (441)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (365)
  3. Michael Postow (364)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (246)
  6. Margaret Callahan (198)

More People

Years
  1. 2025 (28)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (333)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (91)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (345)
  2. American Association for Cancer Research (275)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (90)

More Publishers

Results (1866)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
    Journal Article

    Magahis, P. T.; Corso, T.; Livingstone, P.; Tom, E.; Srivastava, A.; Postow, M.; Faleck, D.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways
    Journal Article

    Lacouture, M. E.; Goleva, E.; Shah, N.; Rotemberg, V.; Kraehenbuehl, L.; Ketosugbo, K. F.; Merghoub, T.; Maier, T.; Bang, A.; Gu, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment
    Journal Article

    Widman, A. J.; Shah, M.; Frydendahl, A.; Halmos, D.; Khamnei, C. C.; Øgaard, N.; Rajagopalan, S.; Arora, A.; Deshpande, A.; Hooper, W. F.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
    Journal Article

    Sacco, J. J.; Carvajal, R. D.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Detection and imaging of multiple immunotherapy markers in the tumor microenvironment with SERS nanoprobes for automated treatment response monitoring
    Conference Paper

    Andreou, C.; Plakas, K.; Berisha, N.; Gigoux, M.; Pal, S.; Merghoub, T.; Detty, M.; Kircher, M.
    SPIE (2024)

    Fulltext@MSK | Save
  • Defining D-irAEs: Consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy
    Journal Article

    Chen, S. T.; Semenov, Y. R.; Alloo, A.; Bach, D. Q.; Betof Warner, A.; Bougrine, A.; Burton, L.; Cappelli, L. C.; Castells, M.; Cohen, J.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: Active drug monitoring to assess the impact of immune response on drug exposure
    Journal Article

    Spreafico, A.; Couselo, E. M.; Irmisch, A.; Bessa, J.; Au-Yeung, G.; Bechter, O.; Svane, I. M.; Sanmamed, M. F.; Gambardella, V.; McKean, M.; more...
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors
    Journal Article

    Francis, J. H.; Barker, C. A.; Canestraro, J.; Abramson, D. H.; Shoushtari, A. N.
    American Journal of Ophthalmology Case Reports (2024)

    Fulltext@MSK | Save
  • Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
    Journal Article

    Callahan, M.; Amin, A.; Kaye, F. J.; Morse, M. A.; Taylor, M. H.; Peltola, K. J.; Sharma, P.; O'Reilly, E. M.; Meadows Shropshire, S.; O'Brien, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save